Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.98), $0.05 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $11.99 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.